A population-based analysis of the risk of drug interaction between clarithromycin and statins for hospitalisation or death

Lipids in Health and Disease

Volumn 14, Issue 1, 2015, Pages

  Mesgarpour, Bita ^a,b   Gouya, Ghazaleh ^a   Herkner, Harald ^c   Reichardt, Berthold ^d   Wolzt, Michael ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d Sickness Fund Burgenland ^*  (Austria)

Author keywords

Clarithromycin; Cohort studies; Drug interactions; Electronic health records; HMG CoA reductase inhibitors

Indexed keywords

ATORVASTATIN; CLARITHROMYCIN; CYTOCHROME P450 3A; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; CYTOCHROME P450 3A INHIBITOR;

ADULT; ARTICLE; AUSTRIA; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DRUG EXPOSURE; DRUG METABOLISM; DRUG POTENTIATION; DRUG UTILIZATION; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INSURANCE; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MORTALITY; PRESCRIPTION; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; AGED; CARDIOVASCULAR DISEASES; DRUG INTERACTION; DYSLIPIDEMIAS; MIDDLE AGED; RISK;

ADULT; AGED; ATORVASTATIN CALCIUM; CARDIOVASCULAR DISEASES; CLARITHROMYCIN; CYTOCHROME P-450 CYP3A INHIBITORS; DRUG INTERACTIONS; DYSLIPIDEMIAS; FEMALE; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PRAVASTATIN; RETROSPECTIVE STUDIES; RISK; ROSUVASTATIN CALCIUM; SIMVASTATIN;

EID: 84945131721     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/s12944-015-0134-y     Document Type: Article

References (30)

1. Cheng JW, Frishman WH, Aronow WS. Updates on cytochrome p450-mediated cardiovascular drug interactions. Dis Mon. 2010;56:163-79.
2. Jana S, Paliwal J. Molecular mechanisms of cytochrome p450 induction: potential for drug-drug interactions. Curr Protein Pept Sci. 2007;8:619-28.
3. Kalra BS. Cytochrome P450 enzyme isoforms and their therapeutic implications: an update. Indian J Med Sci. 2007;61:102-16.
4. Liu YT, Hao HP, Liu CX, Wang GJ, Xie HG. Drugs as CYP3A probes, inducers, and inhibitors. Drug Metab Rev. 2007;39:699-721.
5. Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, Raunio H. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol. 2008;82:667-715.
6. Tanaka E. Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes. J Clin Pharm Ther. 1998;23:403-16.
7. Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab. 2008;9:310-22.
8. Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007;29:687-710.
9. Bakhai A, Rigney U, Hollis S, Emmas C. Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population. Pharmacoepidemiol Drug Saf. 2012;21:485-93.
10. Devold HM, Molden E, Skurtveit S, Furu K. Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy. Br J Clin Pharmacol. 2009;67:234-41.
11. Ming EE, Davidson MH, Gandhi SK, Marotti M, Miles CG, Ke X, et al. Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases. J Clin Lipidol. 2008;2:453-63.
12. Ratz Bravo AE, Tchambaz L, Krahenbuhl-Melcher A, Hess L, Schlienger RG, Krahenbuhl S. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug Saf. 2005;28:263-75.
13. Amsden GW, Kuye O, Wei GC. A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers. J Clin Pharmacol. 2002;42:444-9.
14. Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol. 2004;94:1140-6.
15. Rowan C, Brinker AD, Nourjah P, Chang J, Mosholder A, Barrett JS, et al. Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors. Pharmacoepidemiol Drug Saf. 2009;18:301-9.
16. Arnold C, Lamy O, Hagmann N. [88 years old woman with acute muscular weakness and diffuse muscular pain: have you thought about the drugs?]. Praxis (Bern 1994). 2010;99(24):1507-11.
17. Grunden JW, Fisher KA. Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin. Ann Pharmacother. 1997;31:859-63.
18. Kahri AJ, Valkonen MM, Vuoristo MK, Pentikainen PJ. Rhabdomyolysis associated with concomitant use of simvastatin and clarithromycin. Ann Pharmacother. 2004;38:719.
19. Lee AJ, Maddix DS. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother. 2001;35:26-31.
20. Molden E, Andersson KS. Simvastatin-associated rhabdomyolysis after coadministration of macrolide antibiotics in two patients. Pharmacotherapy. 2007;27:603-7.
21. Page SR, Yee KC. Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin. Intern Med J. 2014;44:690-3.
22. Trieu J, Emmett L, Perera C, Thanakrishnan K, Van Der Wall H. Rhabdomyolysis resulting from interaction of simvastatin and clarithromycin demonstrated by Tc-99 m MDP scintigraphy. Clin Nucl Med. 2004;29:803-4.
23. Wagner J, Suessmair C, Pfister HW. Rhabdomyolysis caused by co-medication with simvastatin and clarithromycin. J Neurol. 2009;256:1182-3.
24. Cziraky MJ, Willey VJ, McKenney JM, Kamat SA, Fisher MD, Guyton JR, et al. Statin safety: an assessment using an administrative claims database. Am J Cardiol. 2006;97:61C-8.
25. Patel AM, Shariff S, Bailey DG, Juurlink DN, Gandhi S, Mamdani M, et al. Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. Ann Intern Med. 2013;158:869-76.
26. Rowan CG, Brunelli SM, Munson J, Flory J, Reese PP, Hennessy S, et al. Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network. Pharmacoepidemiol Drug Saf. 2012;21:494-506.
27. Hutson JR, Fischer HD, Wang X, Gruneir A, Daneman N, Gill SS, et al. Use of clarithromycin and adverse cardiovascular events among older patients receiving donepezil: a population-based, nested case-control study. Drugs Aging. 2012;29:205-11.
28. Gandhi S, Fleet JL, Bailey DG, McArthur E, Wald R, Rehman F, et al. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. JAMA. 2013;310:2544-53.
29. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Geneva: World Health Organization (WHO); 2010.
30. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed in Jan. 2015.